Excelera® Specialty Pharmacy Network Joins Merck’s Commitment to Hepatitis C

To be able to provide Hep C patients access to these important treatments directly at the point of care ensures the best possible utilization and adherence to these therapies.

The Excelera network consists of point-of-care specialty pharmacies owned by health systems and academic medical centers. The network provides members nationally scaled infrastructure and support to help them develop best practices and gain access to limited-distribution drugs and biologics and restrictive payer agreements so members can provide continuity of care for their patients with complex and chronic conditions requiring specialty drugs and biologics. The network also serves as a national platform for collaboration to optimize outpatient specialty drug therapy for population health.

Specialty pharmaceuticals are expensive drugs that require special handing and administration and are often used to treat the most ill and clinically complex patients. The Excelera organization will partner with Merck to ensure that member health system-based specialty pharmacies have access to these important Hep C medications as well as to macrolide antibacterial drug Dificid®.

“To be able to provide Hep C patients access to these important treatments directly at the point of care ensures the best possible utilization and adherence to these therapies,” said Jim Fox, Chief Executive Officer of the Excelera network.

Chronic HCV

Chronic HCV is a contagious liver disease that can lead to serious liver problems, including cirrhosis (scarring of the liver) or liver cancer. Treatment generally includes antiviral medications intended to clear the virus from the patient’s body.

About ZEPATIER ® (elbasvir and grazoprevir) 50mg/100mg Tablets

ZEPATIER is a fixed-dose combination product…

Article Source…

Leave a Reply

Your email address will not be published. Required fields are marked *